Neuritis óptica bilateral secundaria a pembrolizumab. Un evento adverso infrecuente secundario a la administración de inhibidores del check-point: a propósito de un caso

Abstract

Toxicity secondary to checkpoint inhibitors (ICP) can affect numerous parts of the body, with varying frequency. We present a case of bilateral optic neuritis secondary to the use of pembrolizumab (an anti-PD-1), which has been described in the literature in less than 1% of cases associated with the use of anti-PD-1/PD-L1 and anti-CTLA4 (ICP).